Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • Nora AI
  • About Us
    • Our Coverage
    • Team
Third party research

Eevia Health: Navigating a Challenging H2-23 Through Enhanced Efficiency - Analyst Group

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) concludes a transformative 2023, marked by a sharp decline in net sales during H2-23, mainly stemming from the shift away from heavy reliance on a single customer toward a more diversified customer base. Nonetheless, Eevia has demonstrated proof of efficiency, both in terms of production as well as the overall cost structure, underscored by the full year gross margin of 58% and a positive EBITDA result of EUR 0.8m. Based on current estimates and an applied EV/S multiple of 1.2x, a potential present value per share of SEK 2.0 (2.4) is derived in a Base scenario.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.